Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS) (NCT06212193)
Early Feasibility Study (EFS) to Assess the Safety and Performance of the Innoventric Trillium™ Stent Graft in the Treatment of Severe or Greater Tricuspid Regurgitation (TR)
🩺 Plain-English Summary (8th-Grade Level)
Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).
Who can join: Review the eligibility criteria below.
Location: Cardiovascular Institute of Los Robles Health System — Thousand Oaks, California
Age range: 18 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Cardiovascular Institute of Los Robles Health System — Thousand Oaks, California
- Ascension St. John — Detroit, Michigan
- Mayo Clinic Hospital (Rochester) — Rochester, Minnesota
- Weill Cornell Medicine — New York, New York
- Stony Brook Heart Institute — Stony Brook, New York
- The Christ Hospital — Cincinnati, Ohio
- Lankenau Heart Institute — Philadelphia, Pennsylvania
- TriStar Centennial Medical Center — Nashville, Tennessee
- University of Washington Medical Center — Seattle, Washington
- University Medicine Mainz — Mainz, Rhineland-Palatinate
- Helios Health Institute GmbH, Leipzig — Leipzig, Saxony
- German Heart Center at Charité (DHZC) — Berlin, State of Berlin
📞 Contact the Study Coordinator
Phone: +972-52-8981783
Email: chen@innoventric.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Tricuspid Regurgitation
- TRILUMINATE Pivotal Trial — Birmingham, Alabama
- TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I) — Phoenix, Arizona
- TTVR Early Feasibility Study — Birmingham, Alabama
- Clinical Study of Edwards Cardioband FIT Valve Repair System — Chicago, Illinois
- Laplace Early Feasibility Study - Canada — Ottawa, Ontario
- Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System — Tucson, Arizona
Explore by condition: All Tricuspid Regurgitation clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.